Drug Delivery Devices Market to Reach US$ 698.2 Bn by 2031, Growing at 7.4% CAGR as Smart and Wearable Devices Expand: New Report by Wissen Research

Wissen Research projects the global drug delivery devices market will grow from USD 488.6 billion in 2026 to USD 698.2 billion by 2031, a 7.4% CAGR. Growth drivers include chronic disease treatment, biologics and GLP-1 therapies, home healthcare, and connected and wearable delivery systems; Asia-Pacific is forecast to be the fastest-growing region. The release also cites September 2026 Medtronic regulatory submissions and approval, an August distribution partnership, and a July Brazil semaglutide pen launch.

Analysis

The investable signal is narrower than the headline forecast: a broad market estimate does not establish incremental earnings for any listed supplier, and the report provides no segment economics, order data, or company-level revenue exposure. Treat it as a demand backdrop, not a valuation input. The second-order opportunity is in device components and manufacturing capacity, but economics depend on which drugmakers own the device design, supplier awards, and production volumes—not simply on growth in biologics or GLP-1 use. Conversely, a shift toward oral therapies, reusable systems, or alternative delivery formats could dilute injector demand even as total treatment volumes rise.

BDX’s Brazil pen collaboration is a commercial proof point, not evidence of material consolidated sales; uptake, local access, and the underlying therapy’s supply will determine device volumes. Medtronic’s submission and approvals are milestones, not proof of launch timing or adoption. Insulet and other diabetes-device exposure should not be conflated with the broader injectable-device opportunity.

Near term (days), this promotional research release offers little standalone catalyst. Over 1–3 months, look for company guidance, supplier awards, and launch or regulatory updates that validate conversion into orders. Over 6–18 months, capacity utilization and recurring component demand matter more than headline market growth. The contrarian risk is that consensus extrapolates chronic-disease prevalence into device revenue while underweighting reimbursement, usability, formulation compatibility, competition, and development delays. Falsification: relevant firms report no order/guidance improvement, or launches are delayed and expected volumes fail to translate into disclosed sales.

Key Decisions for Investors

• No trade on the market forecast alone. Keep BDX and MDT on a catalyst watchlist; require evidence of launch uptake, device volumes, or a company-level outlook change before adding exposure.
• For WST, STVN, GXI, and YPSN, track disclosed capacity investments, customer wins, and growth in relevant delivery-device sales. Treat broad category demand as an alert, not an earnings forecast; absent that evidence, avoid a basket position.
• Reassess the GLP-1 injector thesis if major therapy makers shift materially toward oral or alternative delivery, reimbursement/access weakens, or suppliers report delayed programs or softer device orders.